Download PDF
Semin Respir Crit Care Med 2011; 32(3): 335-345
DOI: 10.1055/s-0031-1279830
© Thieme Medical Publishers

Management of Alveolar Hemorrhage in Lung Vasculitides

Alina Casian1 , David Jayne1
  • 1Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom
Further Information

Publication History

Publication Date:
14 June 2011 (online)

    Permissions and Reprints

ABSTRACT

Alveolar hemorrhage (AH) is an important pulmonary manifestation of small vessel vasculitis because severe presentations are the most common vasculitic cause of early death. Renal vasculitis is usually present with AH; the combination is known as pulmonary-renal syndrome. Early diagnosis and intensive therapy are of particular importance to reduce early mortality and improve longer-term outcomes. The commonest immune-mediated cause of AH is anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) (80%), with other vasculitides, including systemic lupus erythematosus and anti-glomerular basement membrane disease accounting for 20%. One quarter of AAV patients develop AH, which when mild is associated with a good outcome, but mortality rises to 50% for cases with respiratory failure requiring ventilator support. The prognosis of AH in the other vasculitides is generally favorable, but cases are rare and experience is limited. Treatment follows similar regimens to those for other AAV presentations, although when severe there is widespread use of parenteral glucocorticoids together with plasma exchange. These interventions have developed empirically supported by a theoretical rationale but have not been validated by randomized clinical trials. Sepsis and cardiovascular and thromboembolic events are important early complications. and long-term follow-up is required to monitor for and prevent relapse and manage disease-related damage. A minority of cases develop on a background of pulmonary fibrosis, or progressive pulmonary fibrosis develops after vasculitis has gone into remission.

KEYWORDS

Alveolar - hemorrhage - vasculitis - lung - ANCA - management

REFERENCES

  • 1 Rabe C, Appenrodt B, Hoff C et al.. Severe respiratory failure due to diffuse alveolar hemorrhage: clinical characteristics and outcome of intensive care.  J Crit Care. 2010;  25 (2) 230-235
    CrossrefPubMedGoogle Scholar
  • 2 Casian A L, Berden A, Jayne D RW. Alveolar haemorrhage in ANCA associated vasculitis: a retrospective analysis from the European Vasculitis Study Group.  NDT PLUS. 2010;  3 (suppl 3) iii278
    PubMedGoogle Scholar
  • 3 Guillevin L, Durand-Gasselin B, Cevallos R et al.. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients.  Arthritis Rheum. 1999;  42 (3) 421-430
    CrossrefPubMedGoogle Scholar
  • 4 Hashimoto H, Yano T, Yoshida M et al.. Clinical and epidemiological analysis of anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis from a nationwide survey in 1998 in Japan, Annual Report of The Research Committee of Intractable Vasculitis Diseases, The Ministry of Health and Welfare of Japan, 1999. 
    Google Scholar
  • 5 Travis W D, Carpenter H A, Lie J T. Diffuse pulmonary hemorrhage: an uncommon manifestation of Wegener's granulomatosis.  Am J Surg Pathol. 1987;  11 (9) 702-708
    CrossrefPubMedGoogle Scholar
  • 6 Travis W D, Hoffman G S, Leavitt R Y, Pass H I, Fauci A S. Surgical pathology of the lung in Wegener's granulomatosis: review of 87 open lung biopsies from 67 patients.  Am J Surg Pathol. 1991;  15 (4) 315-333
    CrossrefPubMedGoogle Scholar
  • 7 Yoshimura N, Matsubara O, Tamura A, Kasuga T, Mark E J. Wegener's granulomatosis: associated with diffuse pulmonary hemorrhage.  Acta Pathol Jpn. 1992;  42 (9) 657-661
    PubMedGoogle Scholar
  • 8 Solans R, Bosch J A, Pérez-Bocanegra C et al.. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients.  Rheumatology (Oxford). 2001;  40 (7) 763-771
    CrossrefPubMedGoogle Scholar
  • 9 Clutterbuck E J, Pusey C D. Severe alveolar haemorrhage in Churg-Strauss syndrome.  Eur J Respir Dis. 1987;  71 (3) 158-163
    PubMedGoogle Scholar
  • 10 Lai R-S, Lin S-L, Lai N S, Lee P C. Churg-Strauss syndrome presenting with pulmonary capillaritis and diffuse alveolar hemorrhage.  Scand J Rheumatol. 1998;  27 (3) 230-232
    CrossrefPubMedGoogle Scholar
  • 11 Della Rossa A, Baldini C, Tavoni A et al.. Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre.  Rheumatology (Oxford). 2002;  41 (11) 1286-1294
    CrossrefPubMedGoogle Scholar
  • 12 Papiris S A, Manali E D, Kalomenidis I, Kapotsis G E, Karakatsani A, Roussos C. Bench-to-bedside review: pulmonary-renal syndromes—an update for the intensivist.  Crit Care. 2007;  11 (3) 213
    CrossrefPubMedGoogle Scholar
  • 13 Mark E J, Ramirez J F. Pulmonary capillaritis and hemorrhage in patients with systemic vasculitis.  Arch Pathol Lab Med. 1985;  109 (5) 413-418
    PubMedGoogle Scholar
  • 14 Travis W D, Colby T V, Lombard C, Carpenter H A. A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation.  Am J Surg Pathol. 1990;  14 (12) 1112-1125
    CrossrefPubMedGoogle Scholar
  • 15 Xiao H, Heeringa P, Liu Z et al.. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies.  Am J Pathol. 2005;  167 (1) 39-45
    CrossrefPubMedGoogle Scholar
  • 16 Bansal P J, Tobin M C. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement.  Ann Allergy Asthma Immunol. 2004;  93 (4) 398-401
    CrossrefPubMedGoogle Scholar
  • 17 Xiao H, Heeringa P, Hu P et al.. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.  J Clin Invest. 2002;  110 (7) 955-963
    CrossrefPubMedGoogle Scholar
  • 18 Mukhtyar C, Guillevin L, Cid M C European Vasculitis Study Group et al. EULAR recommendations for the management of primary small and medium vessel vasculitis.  Ann Rheum Dis. 2009;  68 (3) 310-317
    CrossrefPubMedGoogle Scholar
  • 19 Schwarz M I, Brown K K. Small vessel vasculitis of the lung.  Thorax. 2000;  55 (6) 502-510
    CrossrefPubMedGoogle Scholar
  • 20 Ewan P W, Jones H A, Rhodes C G, Hughes J M. Detection of intrapulmonary hemorrhage with carbon monoxide uptake: application in Goodpasture's syndrome.  N Engl J Med. 1976;  295 (25) 1391-1396
    CrossrefPubMedGoogle Scholar
  • 21 Schnabel A, Reuter M, Csernok E, Richter C, Gross W L. Subclinical alveolar bleeding in pulmonary vasculitides: correlation with indices of disease activity.  Eur Respir J. 1999;  14 (1) 118-124
    CrossrefPubMedGoogle Scholar
  • 22 Nada A K, Torres V E, Ryu J H, Lie J T, Holley K E. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients.  Mayo Clin Proc. 1990;  65 (6) 847-856
    PubMedGoogle Scholar
  • 23 Bhanji A, Karim M. Pulmonary fibrosis-an uncommon manifestation of anti-myeloperoxidase-positive systemic vasculitis?.  NDT Plus. 2010;  3 (4) 351-353
    CrossrefPubMedGoogle Scholar
  • 24 Becker-Merok A, Nossent J C, Ritland N. Fibrosing alveolitis predating microscopic polyangiitis.  Scand J Rheumatol. 1999;  28 (4) 254-256
    CrossrefPubMedGoogle Scholar
  • 25 Eschun G M, Mink S N, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis.  Chest. 2003;  123 (1) 297-301
    CrossrefPubMedGoogle Scholar
  • 26 Lauque D, Cadranel J, Lazor R et al.. Microscopic polyangiitis with alveolar hemorrhage: a study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM”O”P).  Medicine Baltimore). 2000;  79 (4) 222-233
    PubMedGoogle Scholar
  • 27 Gal A A, Salinas F F, Staton Jr G W. The clinical and pathological spectrum of antineutrophil cytoplasmic autoantibody-related pulmonary disease: a comparison between perinuclear and cytoplasmic antineutrophil cytoplasmic autoantibodies.  Arch Pathol Lab Med. 1994;  118 (12) 1209-1214
    PubMedGoogle Scholar
  • 28 Stone J H, Merkel P A, Spiera R RAVE-ITN Research Group et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis.  N Engl J Med. 2010;  363 (3) 221-232
    CrossrefPubMedGoogle Scholar
  • 29 Cordier J F, Valeyre D, Guillevin L, Loire R, Brechot J M. Pulmonary Wegener's granulomatosis: a clinical and imaging study of 77 cases.  Chest. 1990;  97 (4) 906-912
    CrossrefPubMedGoogle Scholar
  • 30 Akikusa B, Kondo Y, Irabu N, Yamamoto S, Saiki S. Six cases of microscopic polyarteritis exhibiting acute interstitial pneumonia.  Pathol Int. 1995;  45 (8) 580-588
    CrossrefPubMedGoogle Scholar
  • 31 Watts R, Lane S, Hanslik T et al.. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.  Ann Rheum Dis. 2007;  66 (2) 222-227
    PubMedGoogle Scholar
  • 32 Guillevin L, Mahr A, Cohen P. Systemic necrotizing vasculitides: classifications and therapeutic strategies [in French].  Rev Med Interne. 2003;  24 (3) 172-182
    CrossrefPubMedGoogle Scholar
  • 33 Seror R, Pagnoux C, Ruivard M French Vasculitis Study Group et al. Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial.  Ann Rheum Dis. 2010;  69 (12) 2125-2130
    CrossrefPubMedGoogle Scholar
  • 34 De Groot K, Rasmussen N, Bacon P A et al.. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.  Arthritis Rheum. 2005;  52 (8) 2461-2469
    CrossrefPubMedGoogle Scholar
  • 35 Jones R B, Tervaert J W, Hauser T European Vasculitis Study Group et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.  N Engl J Med. 2010;  363 (3) 211-220
    CrossrefPubMedGoogle Scholar
  • 36 de Groot K, Harper L, Jayne D R EUVAS (European Vasculitis Study Group) et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.  Ann Intern Med. 2009;  150 (10) 670-680
    CrossrefPubMedGoogle Scholar
  • 37 Jayne D R, Gaskin G, Rasmussen N European Vasculitis Study Group et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.  J Am Soc Nephrol. 2007;  18 (7) 2180-2188
    CrossrefPubMedGoogle Scholar
  • 38 Szpirt W M, Heaf J G, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis—a clinical randomized controlled trial.  Nephrol Dial Transplant. 2011;  26 (1) 206-213
    CrossrefPubMedGoogle Scholar
  • 39 Klemmer P J, Chalermskulrat W, Reif M S, Hogan S L, Henke D C, Falk R J. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis.  Am J Kidney Dis. 2003;  42 (6) 1149-1153
    CrossrefPubMedGoogle Scholar
  • 40 Gallagher H, Kwan J T, Jayne D R. Pulmonary renal syndrome: a 4-year, single-center experience.  Am J Kidney Dis. 2002;  39 (1) 42-47
    CrossrefPubMedGoogle Scholar
  • 41 Yamagata K, Hirayama K, Mase K et al.. Apheresis for MPO-ANCA-associated RPGN-indications and efficacy: lessons learned from Japan nationwide survey of RPGN.  J Clin Apher. 2005;  20 (4) 244-251
    CrossrefPubMedGoogle Scholar
  • 42 Levy J B, Hammad T, Coulthart A, Dougan T, Pusey C D. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies.  Kidney Int. 2004;  66 (4) 1535-1540
    CrossrefPubMedGoogle Scholar
  • 43 Serratrice J, Chiche L, Dussol B et al.. Sequential development of perinuclear ANCA-associated vasculitis and anti-glomerular basement membrane glomerulonephritis.  Am J Kidney Dis. 2004;  43 (3) e26-e30
    CrossrefPubMedGoogle Scholar
  • 44 Hasegawa M, Kawamura N, Kasugai M et al.. Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis: report of five cases.  Ther Apher. 2002;  6 (6) 443-449
    CrossrefPubMedGoogle Scholar
  • 45 Betensley A D, Yankaskas J R. Factor VIIA for alveolar hemorrhage in microscopic polyangiitis.  Am J Respir Crit Care Med. 2002;  166 (9) 1291-1292
    PubMedGoogle Scholar
  • 46 Henke D, Falk R J, Gabriel D A. Successful treatment of diffuse alveolar hemorrhage with activated factor VII.  Ann Intern Med. 2004;  140 (6) 493-494
    CrossrefPubMedGoogle Scholar
  • 47 Heslet L, Nielsen J D, Levi M, Sengeløv H, Johansson P I. Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage.  Crit Care. 2006;  10 (6) R177
    CrossrefPubMedGoogle Scholar
  • 48 Ahmed S H, Aziz T, Cochran J, Highland K. Use of extracorporeal membrane oxygenation in a patient with diffuse alveolar hemorrhage.  Chest. 2004;  126 (1) 305-309
    CrossrefPubMedGoogle Scholar
  • 49 Jayne D R, Chapel H, Adu D et al.. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.  QJM. 2000;  93 (7) 433-439
    CrossrefPubMedGoogle Scholar
  • 50 Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients.  Clin Exp Rheumatol. 2007;  25 (1, suppl 44) S23-S27
    PubMedGoogle Scholar
  • 51 Ferraro A J, Day C J, Drayson M T, Savage C O. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis.  Nephrol Dial Transplant. 2005;  20 (3) 622-625
    CrossrefPubMedGoogle Scholar
  • 52 Keogh K A, Ytterbeg S R, Fervenza F C et al.. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.  Am J Respir Crit Care Med. 2006;  173 (7) 815-816
    PubMedGoogle Scholar
  • 53 Lovric S, Erdbruegger U, Kümpers P et al.. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients.  Nephrol Dial Transplant. 2009;  24 (1) 179-185
    CrossrefPubMedGoogle Scholar
  • 54 Bartolucci P, Ramanoelina J, Cohen P et al.. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients.  Rheumatology (Oxford). 2002;  41 (10) 1126-1132
    CrossrefPubMedGoogle Scholar
  • 55 Booth A, Harper L, Hammad T et al.. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.  J Am Soc Nephrol. 2004;  15 (3) 717-721
    CrossrefPubMedGoogle Scholar
  • 56 Flossmann O, Baslund B, Bruchfeld A et al.. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis.  Ann Rheum Dis. 2009;  68 (7) 1125-1130
    CrossrefPubMedGoogle Scholar
  • 57 Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).  Ann Rheum Dis. 2008;  67 (9) 1322-1327
    PubMedGoogle Scholar
  • 58 Jayne D, Rasmussen N, Andrassy K European Vasculitis Study Group et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.  N Engl J Med. 2003;  349 (1) 36-44
    CrossrefPubMedGoogle Scholar
  • 59 Hiemstra T F, Walsh M, Mahr A et al.. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.  JAMA. 2010;  304(21) 2381-2388
    CrossrefPubMedGoogle Scholar
  • 60 Wegener's Granulomatosis Etanercept Trial (WGET) Research Group . Etanercept plus standard therapy for Wegener's granulomatosis.  N Engl J Med. 2005;  352 (4) 351-361
    CrossrefPubMedGoogle Scholar
  • 61 Walsh M, Merkel P A, Mahr A, Jayne D. A systemic review and meta-analysis of relapses in ANCA-associated vasculitis: what is the effect of low-dose corticosteroids?.  J Am Soc Nephrol. 2007;  19 PO919
    PubMedGoogle Scholar
  • 62 Hogan S L, Nachman P H, Wilkman A S, Jennette J C, Falk R J. and The Glomerular Disease Collaborative Network . Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis.  J Am Soc Nephrol. 1996;  7 (1) 23-32
    PubMedGoogle Scholar
  • 63 Holguin F, Ramadan B, Gal A A, Roman J. Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis.  Am J Med Sci. 2008;  336 (4) 321-326
    CrossrefPubMedGoogle Scholar
  • 64 Khan S A, Subla M R, Behl D, Specks U, Afessa B. Outcome of patients with small-vessel vasculitis admitted to a medical ICU.  Chest. 2007;  131 (4) 972-976
    CrossrefPubMedGoogle Scholar
  • 65 Semple D, Keogh J, Forni L, Venn R. Clinical review: vasculitis on the intensive care unit, II: Treatment and prognosis.  Crit Care. 2005;  9 (2) 193-197
    CrossrefPubMedGoogle Scholar
  • 66 Gordon M, Luqmani R A, Adu D et al.. Relapses in patients with a systemic vasculitis.  Q J Med. 1993;  86 (12) 779-789
    PubMedGoogle Scholar
  • 67 Nachman P H, Hogan S L, Jennette J C, Falk R J. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis.  J Am Soc Nephrol. 1996;  7 (1) 33-39
    PubMedGoogle Scholar
  • 68 Savage C OS, Winearls C G, Evans D J, Rees A J, Lockwood C M. Microscopic polyarteritis: presentation, pathology and prognosis.  Q J Med. 1985;  56 (220) 467-483
    PubMedGoogle Scholar
  • 69 Matsumoto T, Homma S, Okada M et al.. The lung in polyarteritis nodosa: a pathologic study of 10 cases.  Hum Pathol. 1993;  24 (7) 717-724
    CrossrefPubMedGoogle Scholar
  • 70 Gómez-Puerta J A, Espinosa G, Morlà R, Cid M C, Cervera R. et al. Interstitial lung disease as a presenting manifestation of microscopic polyangiitis successfully treated with mycophenolate mofetil.  Clin Exp Rheumatol. 2009;  27 (1) 166-167
    PubMedGoogle Scholar
  • 71 Brugiere O, Raffy O, Sleiman C et al.. Progressive obstructive lung disease associated with microscopic polyangiitis.  Am J Respir Crit Care Med. 1997;  155 (2) 739-742
    PubMedGoogle Scholar
  • 72 Komócsi A, Reuter M, Heller M, Muraközi H, Gross W L, Schnabel A. Active disease and residual damage in treated Wegener's granulomatosis: an observational study using pulmonary high-resolution computed tomography.  Eur Radiol. 2003;  13 (1) 36-42
    PubMedGoogle Scholar
  • 73 Amital H, Rubinow A, Naparstek Y. Alveolar hemorrhage in cryoglobulinemia—an indicator of poor prognosis.  Clin Exp Rheumatol. 2005;  23 (5) 616-620
    PubMedGoogle Scholar
  • 74 Rodríguez-Vidigal F F, Roig Figueroa V, Pérez-Lucena E et al.. Alveolar hemorrhage in mixed cryoglobulinemia associated with hepatitis C virus infection [in Spanish].  Med Interna. 1998;  15 (12) 661-663
    PubMedGoogle Scholar
  • 75 Gómez-Tello V, Oñoro-Cañaveral J J, de la Casa Monje R M et al.. Diffuse recidivant alveolar hemorrhage in a patient with hepatitis C virus-related mixed cryoglobulinemia.  Intensive Care Med. 1999;  25 (3) 319-322
    CrossrefPubMedGoogle Scholar
  • 76 Cazzato S, Bernardi F, Cinti C et al.. Pulmonary function abnormalities in children with Henoch-Schönlein purpura.  Eur Respir J. 1999;  13 (3) 597-601
    CrossrefPubMedGoogle Scholar
  • 77 Chaussain M, de Boissieu D, Kalifa G et al.. Impairment of lung diffusion capacity in Schönlein-Henoch purpura.  J Pediatr. 1992;  121 (1) 12-16
    PubMedGoogle Scholar
  • 78 Cream J J, Gumpel J M, Peachey R D. Schönlein-Henoch purpura in the adult: a study of 77 adults with anaphylactoid or Schönlein-Henoch purpura.  Q J Med. 1970;  39 (156) 461-484
    PubMedGoogle Scholar
  • 79 Kathuria S, Cheifec G. Fatal pulmonary Henöch-Schonlein syndrome.  Chest. 1982;  82 (5) 654-656
    CrossrefPubMedGoogle Scholar
  • 80 Olson J C, Kelly K J, Pan C G, Wortmann D W. Pulmonary disease with hemorrhage in Henoch-Schöenlein purpura.  Pediatrics. 1992;  89 (6 Pt 2) 1177-1181
    PubMedGoogle Scholar
  • 81 Paller A S, Kelly K, Sethi R. Pulmonary hemorrhage: an often fatal complication of Henoch-Schoenlein purpura.  Pediatr Dermatol. 1997;  14 (4) 299-302
    CrossrefPubMedGoogle Scholar
  • 82 Vats K R, Vats A, Kim Y, Dassenko D, Sinaiko A R. Henoch-Schönlein purpura and pulmonary hemorrhage: a report and literature review.  Pediatr Nephrol. 1999;  13 (6) 530-534
    CrossrefPubMedGoogle Scholar
  • 83 Tiryaki O, Buyukhatipoglu H, Karakok M, Usalan C. Successful treatment of a rare complication of Henoch-Schönlein purpura in advanced age: pulmonary hemorrhage.  Intern Med. 2007;  46 (12) 905-907
    CrossrefPubMedGoogle Scholar
  • 84 Payton C D, Allison M EM, Boulton-Jones J M. Henoch Schonlein purpura presenting with pulmonary haemorrhage.  Scott Med J. 1987;  32 (1) 26-27
    PubMedGoogle Scholar
  • 85 Matsubayashi R, Matsubayashi T, Fujita N, Yokota T, Ohro Y, Enoki H. Pulmonary hemorrhage associated with Henoch-Schönlein purpura in a child.  Clin Rheumatol. 2008;  27 (6) 803-805
    CrossrefPubMedGoogle Scholar
  • 86 Nick J, Tuder R, May R, Fisher J. Polyarteritis nodosa with pulmonary vasculitis.  Am J Respir Crit Care Med. 1996;  153 (1) 450-453
    PubMedGoogle Scholar
  • 87 Menon Y, Singh R, Cuchacovich R, Espinoza L R. Pulmonary involvement in hepatitis B-related polyarteritis nodosa.  Chest. 2002;  122 (4) 1497-1498
    CrossrefPubMedGoogle Scholar
  • 88 Huong Dle T, Andreu M R, Duhaut P, Godeau P, Piette J C. Intra-alveolar haemorrhage in temporal arteritis.  Ann Rheum Dis. 2003;  62 (2) 189-190
    CrossrefPubMedGoogle Scholar
  • 89 Kissin E Y, Merkel P A. Diagnostic imaging in Takayasu arteritis.  Curr Opin Rheumatol. 2004;  16 (1) 31-37
    CrossrefPubMedGoogle Scholar
  • 90 Vanoli M, Castellani M, Bacchiani G et al.. Non-invasive assessment of pulmonary artery involvement in Takayasu's arteritis.  Clin Exp Rheumatol. 1999;  17 (2) 215-218
    PubMedGoogle Scholar
  • 91 Sharma S, Kamalakar T, Rajani M, Talwar K K, Shrivastava S. The incidence and patterns of pulmonary artery involvement in Takayasu's arteritis.  Clin Radiol. 1990;  42 (3) 177-181
    CrossrefPubMedGoogle Scholar
  • 92 Savage B J, Gupta R K, Angle J, Okusa M D. Takayasu arteritis presenting as a pulmonary-renal syndrome.  Am J Med Sci. 2003;  325 (5) 275-281
    CrossrefPubMedGoogle Scholar
  • 93 Koyabu S, Isaka N, Yada T, Konishi T, Nakano T. Severe respiratory failure caused by recurrent pulmonary hemorrhage in Takayasu's arteritis.  Chest. 1993;  104 (6) 1905-1906
    CrossrefPubMedGoogle Scholar
  • 94 Cilli A, Ozdemir T, Oğüş C. Takayasu's arteritis presenting with bilateral parenchymal consolidations and severe respiratory failure.  Respiration. 2001;  68 (6) 628-630
    CrossrefPubMedGoogle Scholar
  • 95 Afessa B, Tefferi A, Litzow M R, Peters S G. Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients.  Am J Respir Crit Care Med. 2002;  166 (10) 1364-1368
    CrossrefPubMedGoogle Scholar

David JayneM.D. 

Addenbrooke's Hospital, Box 57, Vasculitis Clinic, Hills Road

Cambridge CB2 0QQ, UK

Email: dj106@cam.ac.uk